NBY  Novabay Pharmaceuticals Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.10 (-2.53%)

Company Metrics

  • P/E 0
  • P/S 6.16
  • P/B 27.9
  • EPS -3.87
  • Cash ROIC 921.20%
  • Cash Ratio 0.51
  • Dividend 0 / N/A %
  • Avg. Vol. 129,551.00
  • Shares 2.78M
  • Market Cap. 43.32M

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


NovaBay Pharmaceuticals Inc.
MarketWatch - Jul 16, 2010
NovaBay Pharmaceuticals Inc. NYSE MKT: NBY. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
News NovaBay Pharmaceuticals Inc.NBY
Wall Street Journal - Feb 11, 2011
News NovaBay Pharmaceuticals Inc.NBY. Significant News Only. 10/03/16; Press Release. NovaBay Pharmaceuticals Receives $7 Million from Early Warrant Exercise.
Where Does NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY) Have Its Focus This Year?
Scibility Media - Aug 15, 2016
NovaBay Pharmaceuticals, Inc. (NYSEMKT: NBY) has set for itself many targets to hit before the end of 2016. But there is one that the management of the company has been talking about repeatedly: achieving positive cash flow.
NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova ...
Business Wire (press release) - Nov 19, 2015
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) announces a corporate restructuring to focus on the commercialization of its prescription Avenova┬« Lid and Lash Cleanser. NovaBay is also taking steps to reduce operating expenses ...
Company Update (NYSE:NBY): NovaBay Pharmaceuticals, Inc.'s Auriclosene ...
Smarter Analyst - Sep 19, 2016
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) announces that data from a Phase 2b clinical study with Auriclosene Irrigating Solution (AIS) demonstrated statistically significant and clinically meaningful results in the prevention of urinary catheter ...
Novabay Pharma boosted by catheter blockage trial - Proactive Investors USA & Canada
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) present new data from its anti-infectives
Benchmark Monitor - 14 hours ago
On last trading day, Allergan plc (NYSE:AGN) shares closed at $225.93 per share. AGN market capitalization is 89.29B with beta of 1.03.
NovaBay Pharmaceuticals Announces Partnership with ALPHAEON to Bring Avenova ...
Business Wire (press release) - Sep 24, 2015
IRVINE, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--ALPHAEON Corporation and NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY) announced today that they have formed a partnership that will add NovaBay's breakthrough Avenova to the products ...
Stock Dragged Lower Pre-Market as it Gaps Down: NovaBay Pharmaceuticals, Inc ...
CSZ News - Oct 24, 2016
NovaBay Pharmaceuticals, Inc. (:NBY) stock is gapping down before the bell, indicating risk for investors. This stock should be on high alert today as traders determine whether the selling will continue or if the stock will reverse course today.
NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results
Business Wire (press release) - Aug 11, 2016
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova lid and lash hygiene product for the domestic eye care market, reports financial results for the three ...
NovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q2 2016 Results ... - Seeking Alpha
NovaBay Pharmaceuticals Provides Update on Avenova Sales Growth, Reports ...
Business Wire (press release) - Oct 8, 2015
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, announces that ...